Vein 360 appears in FDA's 510(k) database as the applicant for K260708, a Traditional premarket notification assigned product code FGB and regulation 21 CFR 876.1500, with a decision of Substantially Equivalent dated 2026-10-20. The record was received on 2026-03-04 and reviewed by the Gastroenterology, Urology panel. The device names as filed identify reprocessed LithoVue digital flexible ureteroscopes in two deflection configurations. The supplied portfolio snapshot contains one linked record, all in the 510(k) pathway, and the record sample likewise contains that single entry; these counts describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1][3][4][8]

The K260708 filing and its scope

K260708 lists Vein 360 as applicant, with a filing address in Cincinnati, Ohio, and a device class of 2. FDA's decision description is Substantially Equivalent, the clearance type is Traditional, the third-party review flag is N, and the submission includes a Summary rather than only a statement. The advisory committee is recorded as Gastroenterology, Urology, matching the device classification name Ureteroscope And Accessories, Flexible/Rigid. [1][4][8]

The device name as filed covers two named configurations: Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Standard Deflection) and Vein360 Reprocessed LithoVue Digital Flexible Ureteroscope (Reverse Deflection). Both appear under the same K number and product code, so the clearance is documented at the level of these two reprocessed ureteroscope variants rather than as a broader product family. [1][3][8]

Reprocessing context and predicate comparison

The product names state that the devices are reprocessed, and one indexed summary page records a conclusion by Vein360 that the subject devices are as safe, as effective, and perform as well as the predicate devices, alongside a reference to other reprocessors. That statement is the applicant's conclusion as reproduced by the index; the public documents do not include independent clinical performance data, and no efficacy figures are documented here. [3]

LithoVue is identified by Boston Scientific as a single-use digital flexible ureteroscope, with a specifications page describing the system and linking to indications, safety and warnings material. The public documents do not establish the predicate device selected in K260708, so the relationship between the Vein360 reprocessed devices and any specific Boston Scientific model remains unknown beyond the product naming. [7]

Company-published positioning

Vein360's own website describes a mission of helping clinic partners recover cost through product recovery and purchasing solutions, stating that the company has delivered healthcare supply chain savings and kept devices out of landfill. The same site presents IVUS and RFA catheters as products and describes in-line testing of IVUS catheters on the flexible circuit and 64-element transducer array. These are company statements published by Vein360, not findings of the FDA filing. [5][6]

A LinkedIn company page attributed to Vein360 describes an approach to reducing radiofrequency ablation catheter costs for vein centers and names leadership backgrounds including a surgeon, a biomedical engineer and a reprocessing expert. The public documents do not verify ownership, parent companies, brand relationships or commercial availability of the ureteroscopes, and the FDA filing address is not treated here as a headquarters. [9]

What the record does and does not show

The supplied collection contains one linked record, a 510(k) with a Substantially Equivalent decision, and the record sample contains that same single entry. No recall records appear in the supplied sample. These are snapshot counts of supplied filings and should not be read as measures of total clearances, market share or safety performance. [1][4]

Several third-party indexes reproduce the same K260708 details, including the applicant name, product code, regulation, class and decision date, and one notes that it is unofficial and independent of the FDA. The official FDA database entry and the FDA 510(k) notification page remain the primary references for the filing. [2][4][8]